Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice

International Journal of Cancer

Volumn 50, Issue 3, 1992, Pages 493-499

  Mastino, Antonio ^a   Favalli, Cartesio ^a   Grelli, Sandro ^a   Rasi, Guido ^a   Pica, Francesca ^a   Goldstein, Allan L ^b   Garaci, Enrico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 2; THYMOSIN ALPHA1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL DIVISION; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; SPLEEN; SUPPORT, NON-U.S. GOV'T; THYMOSIN;

EID: 0026586234     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910500327     Document Type: Article

References (31)

1. Modulation of natural killer activity by thymosin alpha 1 and interferon
2. 1 and alpha‐beta interferon on NK activity in tumor‐bearing mice
3. Tumor immunotherapy by local injection of interleukin‐2 and non‐reactive lymphocytes
4. 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice
5. Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide
6. Lymphokine activated killer cell phenomenon. I. Lysis of natural killer‐resistant fresh solid tumor cells by interleukin‐2‐activated autologous human peripheral blood lymphocytes
7. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity
8. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine‐activated killer cells in tumor tissue of mice previously treated with cyclophosphamide
9. 1, recombinant interleukin‐2, recombinant interferon‐β, and recombinant tumor necrosis factor on subcutaneously implanted adenocarcinoma 755 and Lewis lung carcinoma
10. In vivo antitumor activity of multiple injections of recombinant interleukin‐2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors
11. Phenotypic characterization of murine tumor‐infiltrating T lymphocytes
12. Thymosin alpha 1 modulates the expression of high affinity interleukin‐2 receptors on normal human lymphocytes
13. In vivo administration of purified human interleukin‐2. I. Half life and immunological effects of Jurkat cell‐line derived interleukin‐2
14. In vivo administration of purified human interleukin‐2. II. Half life immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL‐2
15. 1 potentiates interleukin 2 induced cytotoxic activity in mice
16. Synergistic antitumor effects of immunotherapy with recombinant interleukin‐2 and recombinant tumor necrosis factor‐α
17. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin‐2
18. The anti‐tumor efficacy of lymphokine‐activated killer cells and recombinant interleukin‐2 in vivo
19. Synergistic antitumor activity of interleukin‐2 and cimetidine against syngeneic murine tumor
20. Cyclophosphamide‐facilitated adoptive immunotherapy of established tumor depends on elimination of tumor induced suppressor cell
21. Combined effects of chemotherapy and interleukin‐2 in the therapy of mice with advanced pulmonary tumors
22. Immunotherapy of cancer using interleukin‐2— current status and future prospects
23. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high‐dose recombinant interleukin‐2
24. A new approach to the adoptive immunotherapy of cancer with tumor‐infiltrating lymphocytes
25. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin‐2
26. 1 in patients with lung cancer
27. Modulation of human natural killer cell cytotoxic activity; lymphokine production and interleukin‐2 receptor expression by thymic hormones
28. Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells
29. Age‐dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients
30. Modulation of interleukin‐2 receptor expression on normal human lymphocytes by thymic hormones
31. Effect of low‐dose cyclophosphamide therapy on specific and nonspecific T cell‐dependent immune response of spleen cells from mice bearing large MOPC‐315 plasmacy‐ tomas